3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
13
Rituximab
11
obinutuzumab
6
fludarabine phosphate
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
ibrutinib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Lenalidomide
5
Etoposide
5
Doxorubicin
5
Biopsy
5
tocilizumab
4
Whole-Body Irradiation
4
venetoclax
3
polatuzumab vedotin
3
glofitamab
3
acalabrutinib
3
Vincristine
3
Mycophenolic Acid
3
Leukapheresis
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
Busulfan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
ARQ531
×
30 days
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled